4//SEC Filing
Riley Antony A 4
Accession 0001339375-26-000002
CIK 0001419041other
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 4:04 PM ET
Size
11.3 KB
Accession
0001339375-26-000002
Insider Transaction Report
Form 4
Riley Antony A
CHIEF FINANCIAL OFFICER
Transactions
- Purchase
Common Stock
2025-12-30$26.33/sh+9,680$254,833→ 41,520 total - Exercise/Conversion
Common Stock
2026-01-01+375→ 41,895 total - Tax Payment
Common Stock
2026-01-01$27.27/sh−154$4,200→ 41,741 total - Exercise/Conversion
Restricted Stock Units
2026-01-01−375→ 1,500 total→ Common Stock (375 underlying)
Footnotes (4)
- [F1]Represents the weighted average share price of an aggregate total of 9,680 shares purchased in the price range of $26.2243 to $26.59 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
- [F3]On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld.
- [F4]Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.
Documents
Issuer
Forte Biosciences, Inc.
CIK 0001419041
Entity typeother
Related Parties
1- filerCIK 0001339375
Filing Metadata
- Form type
- 4
- Filed
- Jan 1, 7:00 PM ET
- Accepted
- Jan 2, 4:04 PM ET
- Size
- 11.3 KB